OBJECTIVE: Rapidly predicting future outcomes based on short-term clinical response would be helpful to optimize rheumatoid arthritis (RA) management in early disease. Our aim was to derive and validate a clinical prediction rule to predict low disease activity (LDA) at 1 year among patients participating in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial escalating RA therapy by adding eitheretanercept or sulfasalazine + hydroxychloroquine [triple therapy (TT)] after 6 months of methotrexate (MTX) therapy. METHODS:Eligible subjects included in the derivation cohort (used for model building, n = 186) were participants with moderate or higher disease activity [Disease Activity Score 28-erythrocyte sedimentation rate (DAS-ESR) > 3.2] despite 24 weeks of MTX monotherapy who added either etanercept or sulfasalazine + hydroxychloroquine. Clinical characteristics measured within the next 12 weeks were used to predict LDA 1 year later using multivariable logistic regression. Validation was performed in the cohort of TEAR patients randomized to initially receive either MTX + etanercept or TT. RESULTS: The derivation cohort yielded 3 prediction models of varying complexity that included age, DAS28 at various timepoints, body mass index, and ESR (area under the receiver-operator characteristic curve up to 0.83). Accuracy of the prediction models ranged between 80% and 95% in both derivation and validation cohorts, depending on the complexity of the model and the cutpoints chosen for response and nonresponse. About 80% of patients could be predicted to be responders or nonresponders at Week 12. CONCLUSION: Clinical data collected early after starting or escalating disease-modifying antirheumatic drug/biologic treatment could accurately predict LDA at 1 year in patients with early RA. For patients predicted to be nonresponders, treatment could be changed at 12 weeks to optimize outcomes.
RCT Entities:
OBJECTIVE: Rapidly predicting future outcomes based on short-term clinical response would be helpful to optimize rheumatoid arthritis (RA) management in early disease. Our aim was to derive and validate a clinical prediction rule to predict low disease activity (LDA) at 1 year among patients participating in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial escalating RA therapy by adding either etanercept or sulfasalazine + hydroxychloroquine [triple therapy (TT)] after 6 months of methotrexate (MTX) therapy. METHODS: Eligible subjects included in the derivation cohort (used for model building, n = 186) were participants with moderate or higher disease activity [Disease Activity Score 28-erythrocyte sedimentation rate (DAS-ESR) > 3.2] despite 24 weeks of MTX monotherapy who added either etanercept or sulfasalazine + hydroxychloroquine. Clinical characteristics measured within the next 12 weeks were used to predict LDA 1 year later using multivariable logistic regression. Validation was performed in the cohort of TEAR patients randomized to initially receive either MTX + etanercept or TT. RESULTS: The derivation cohort yielded 3 prediction models of varying complexity that included age, DAS28 at various timepoints, body mass index, and ESR (area under the receiver-operator characteristic curve up to 0.83). Accuracy of the prediction models ranged between 80% and 95% in both derivation and validation cohorts, depending on the complexity of the model and the cutpoints chosen for response and nonresponse. About 80% of patients could be predicted to be responders or nonresponders at Week 12. CONCLUSION: Clinical data collected early after starting or escalating disease-modifying antirheumatic drug/biologic treatment could accurately predict LDA at 1 year in patients with early RA. For patients predicted to be nonresponders, treatment could be changed at 12 weeks to optimize outcomes.
Authors: Hamed Rezaei; Saedis Saevarsdottir; Kristina Forslind; Kristina Albertsson; Helena Wallin; Johan Bratt; Sofia Ernestam; Pierre Geborek; Ingemar F Pettersson; Ronald F van Vollenhoven Journal: Ann Rheum Dis Date: 2011-09-19 Impact factor: 19.103
Authors: Leann B Maska; Harlan R Sayles; James R O'Dell; Jeffrey R Curtis; S Louis Bridges; Larry W Moreland; Stacey S Cofield; Ted R Mikuls Journal: Arthritis Care Res (Hoboken) Date: 2012-12 Impact factor: 4.794
Authors: Margaret H Y Ma; Fowzia Ibrahim; David Walker; Andrew Hassell; Ernest H Choy; Patrick D W Kiely; Richard Williams; David A Walsh; Adam Young; David L Scott Journal: J Rheumatol Date: 2012-01-15 Impact factor: 4.666
Authors: Larry W Moreland; James R O'Dell; Harold E Paulus; Jeffrey R Curtis; Joan M Bathon; E William St Clair; S Louis Bridges; Jie Zhang; Theresa McVie; George Howard; Désirée van der Heijde; Stacey S Cofield Journal: Arthritis Rheum Date: 2012-09
Authors: M F Bakker; J W G Jacobs; P M J Welsing; S A Vreugdenhil; C van Booma-Frankfort; S P Linn-Rasker; E Ton; F P J G Lafeber; J W J Bijlsma Journal: Ann Rheum Dis Date: 2011-03-15 Impact factor: 19.103
Authors: Jeffrey R Curtis; Shuo Yang; Lang Chen; Grace S Park; Bojena Bitman; Brian Wang; Iris Navarro-Millan; Arthur Kavanaugh Journal: Ann Rheum Dis Date: 2011-10-13 Impact factor: 19.103
Authors: Désirée van der Heijde; Edward C Keystone; Jeffrey R Curtis; Robert B Landewé; Michael H Schiff; Dinesh Khanna; Tore K Kvien; Lucian Ionescu; Leon M Gervitz; Owen R Davies; Kristel Luijtens; Daniel E Furst Journal: J Rheumatol Date: 2012-05-15 Impact factor: 4.666
Authors: Sudha Visvanathan; Mahboob U Rahman; Edward Keystone; Mark Genovese; Lars Klareskog; Elizabeth Hsia; Michael Mack; Jacqui Buchanan; Michael Elashoff; Carrie Wagner Journal: Arthritis Res Ther Date: 2010-11-17 Impact factor: 5.156
Authors: Veena K Ranganath; Kambiz Motamedi; Espen A Haavardsholm; Paul Maranian; David Elashoff; Fiona McQueen; Erin L Duffy; Joan M Bathon; Jeffrey R Curtis; Weiling Chen; Larry Moreland; James Louie; Sogol Amjadi; James O'Dell; Stacey S Cofield; E William St Clair; S Louis Bridges; Harold E Paulus Journal: Arthritis Care Res (Hoboken) Date: 2015-07 Impact factor: 4.794
Authors: James R O'Dell; Jeffrey R Curtis; Ted R Mikuls; Stacey S Cofield; S Louis Bridges; Veena K Ranganath; Larry W Moreland Journal: Arthritis Rheum Date: 2013-08
Authors: Theresa Wampler Muskardin; Priyanka Vashisht; Jessica M Dorschner; Mark A Jensen; Beverly S Chrabot; Marlena Kern; Jeffrey R Curtis; Maria I Danila; Stacey S Cofield; Nancy Shadick; Peter A Nigrovic; E William St Clair; Clifton O Bingham; Richard Furie; William Robinson; Mark Genovese; Christopher C Striebich; James R O'Dell; Geoffrey M Thiele; Larry W Moreland; Marc Levesque; S Louis Bridges; Peter K Gregersen; Timothy B Niewold Journal: Ann Rheum Dis Date: 2015-11-06 Impact factor: 19.103
Authors: Jeffrey R Curtis; Melvin Churchill; Alan Kivitz; Ahmed Samad; Laura Gauer; Leon Gervitz; Willem Koetse; Jeffrey Melin; Yusuf Yazici Journal: Arthritis Rheumatol Date: 2015-12 Impact factor: 10.995
Authors: Mária Filková; Borbala Aradi; Ladislav Senolt; Caroline Ospelt; Serena Vettori; Heřman Mann; Andrew Filer; Karim Raza; Christopher D Buckley; Martyn Snow; Jiří Vencovský; Karel Pavelka; Beat A Michel; Renate E Gay; Steffen Gay; Astrid Jüngel Journal: Ann Rheum Dis Date: 2013-07-29 Impact factor: 19.103